157 related articles for article (PubMed ID: 2282562)
21. Outcome of treatment of hyperthyroidism.
Bringmann IM; van Leeuwen BL; Hennemann G; Beckett GJ; Toft AD
J Endocrinol Invest; 1999 Apr; 22(4):250-6. PubMed ID: 10342357
[TBL] [Abstract][Full Text] [Related]
22. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves' disease hyperthyroidism.
Gómez-Arnaiz N; Andía E; Gumà A; Abós R; Soler J; Gómez JM
Horm Metab Res; 2003 Aug; 35(8):492-7. PubMed ID: 12953167
[TBL] [Abstract][Full Text] [Related]
23. Radioactive iodine therapy for pediatric Graves' disease: a single-center experience over a 10-year period.
Kaplowitz PB; Jiang J; Vaidyanathan P
J Pediatr Endocrinol Metab; 2020 Mar; 33(3):383-389. PubMed ID: 31603857
[TBL] [Abstract][Full Text] [Related]
24. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves' disease.
Nygaard B; Hegedüs L; Gervil M; Hjalgrim H; Hansen BM; Søe-Jensen P; Hansen JM
J Intern Med; 1995 Dec; 238(6):491-7. PubMed ID: 9422034
[TBL] [Abstract][Full Text] [Related]
25. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment.
Stan MN; Durski JM; Brito JP; Bhagra S; Thapa P; Bahn RS
Thyroid; 2013 May; 23(5):620-5. PubMed ID: 23205939
[TBL] [Abstract][Full Text] [Related]
26. 125I therapy in Graves' disease. Long-term results in 355 patients.
McDougall IR; Greig WR
Ann Intern Med; 1976 Dec; 85(6):720-3. PubMed ID: 1036667
[TBL] [Abstract][Full Text] [Related]
27. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study.
Andrade VA; Gross JL; Maia AL
J Clin Endocrinol Metab; 2001 Aug; 86(8):3488-93. PubMed ID: 11502768
[TBL] [Abstract][Full Text] [Related]
28. Three basic patterns of changes in serum thyroid hormone levels in Graves' disease during the one-year period after radioiodine therapy.
Nakajo M; Tsuchimochi S; Tanabe H; Nakabeppu Y; Jinguji M
Ann Nucl Med; 2005 Jun; 19(4):297-308. PubMed ID: 16097639
[TBL] [Abstract][Full Text] [Related]
29. Comparative evaluation of two fixed doses of 185 and 370 MBq 131I, for the treatment of Graves' disease resistant to antithyroid drugs.
Esfahani AF; Kakhki VR; Fallahi B; Eftekhari M; Beiki D; Saghari M; Takavar A
Hell J Nucl Med; 2005; 8(3):158-61. PubMed ID: 16390021
[TBL] [Abstract][Full Text] [Related]
30. Radiometabolic treatment of hyperthyroidism with a calculated dose of 131-iodine: results of one-year follow-up.
Regalbuto C; Marturano I; Condorelli A; Latina A; Pezzino V
J Endocrinol Invest; 2009 Feb; 32(2):134-8. PubMed ID: 19411811
[TBL] [Abstract][Full Text] [Related]
31. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
Chen DY; Chen TH
Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
[TBL] [Abstract][Full Text] [Related]
32. [Results of radioiodine therapy of manifest hyperthyroidism and autonomous struma with euthyroidism].
Berding G; Schicha H
Nuklearmedizin; 1990 Aug; 29(4):158-65. PubMed ID: 2216811
[TBL] [Abstract][Full Text] [Related]
33. The early development of transient and permanent hypothyroidism following radioiodine therapy for hyperthyroid Graves' disease.
Peden NR; Hart IR
Can Med Assoc J; 1984 May; 130(9):1141-4. PubMed ID: 6546895
[TBL] [Abstract][Full Text] [Related]
34. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients.
Hu RT; Liu DS; Li B
BMC Endocr Disord; 2020 May; 20(1):76. PubMed ID: 32471411
[TBL] [Abstract][Full Text] [Related]
35. Long-term results following 131I treatment for Graves' disease in Hong Kong Chinese--discriminant factors predicting hypothyroidism.
Kung AW; Pun KK; Lam KS; Choi P; Wang C; Yeung RT
Q J Med; 1990 Sep; 76(281):961-7. PubMed ID: 2236479
[TBL] [Abstract][Full Text] [Related]
36. The occurrence of hypothyroidism following radioactive iodine treatment of toxic nodular goiter is related to the TSH level.
Adamali HI; Gibney J; O'Shea D; Casey M; McKenna TJ
Ir J Med Sci; 2007 Sep; 176(3):199-203. PubMed ID: 17632747
[TBL] [Abstract][Full Text] [Related]
37. A possible method using baseline hormonal levels to prescribe the appropriate oral therapeutic radioiodine dosage for Graves' disease.
Nakajo M; Tsuchimochi S; Jinguji M; Tanabe H; Umanodan T; Nakabeppu Y
Ann Nucl Med; 2007 Oct; 21(8):471-6. PubMed ID: 17952556
[TBL] [Abstract][Full Text] [Related]
38. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome.
Allahabadia A; Daykin J; Sheppard MC; Gough SC; Franklyn JA
J Clin Endocrinol Metab; 2001 Aug; 86(8):3611-7. PubMed ID: 11502786
[TBL] [Abstract][Full Text] [Related]
39. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
Berg GE; Michanek AM; Holmberg EC; Fink M
J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
[TBL] [Abstract][Full Text] [Related]
40. Radioiodine-induced hypothyroidism in Graves' disease: factors associated.
Cunnien AJ; Hay ID; Gorman CA; Offord KP; Scanlon PW
J Nucl Med; 1982 Nov; 23(11):978-83. PubMed ID: 6897075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
